Health
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Headline as filed by MarketWatch.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| MarketWatch | This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month |
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring. |
0m | marketwatch.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.